Search research articles
Contact Us
Filters
Showing results (81-90 of 154) with videos related to
Page
of 16
Sort By:
Cancer Medicine
|
July 15, 2021
Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry
Angelo Belotti, Rossella Ribolla, Valeria Cancelli, et al.
Leukemia
|
January 22, 2026
Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia
Michela Ansuinelli, Nadia Peragine, Maria Stefania De Propris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 27, 2013
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi
Massimo Federico, Stefano Luminari, Alessandra Dondi, et al.
American Journal of Hematology
|
October 21, 2014
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi
Giuseppe Rossi, Luigi Marcheselli, Alessandra Dondi, et al.
Haematologica
|
November 8, 2011
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers
Francesco Zaja, Stefano De Luca, Umberto Vitolo, et al.
British Journal of Haematology
|
December 24, 2021
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial
Annalisa Chiappella, Fary Diop, Claudio Agostinelli, et al.
Journal of Geriatric Oncology
|
July 13, 2019
Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi
Francesco Merli, Federica Cavallo, Flavia Salvi, et al.
Annals of Hematology
|
December 25, 2019
The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments
Alessia Bari, Raffaella Marcheselli, Stefano Sacchi, et al.
Haematologica
|
January 18, 2015
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study
Davide Rossi, Alessio Bruscaggin, Piera La Cava, et al.
Leukemia & Lymphoma
|
September 8, 2011
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi
Francesco Merli, Stefano Luminari, Giuseppe Rossi, et al.
Page
of 16
Search research articles
Search
Showing results (81-90 of 154) with videos related to
Sort By:
Page
of 16
Cancer Medicine
|
July 15, 2021
Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry
Angelo Belotti, Rossella Ribolla, Valeria Cancelli, et al.
Leukemia
|
January 22, 2026
Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia
Michela Ansuinelli, Nadia Peragine, Maria Stefania De Propris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 27, 2013
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi
Massimo Federico, Stefano Luminari, Alessandra Dondi, et al.
American Journal of Hematology
|
October 21, 2014
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi
Giuseppe Rossi, Luigi Marcheselli, Alessandra Dondi, et al.
Haematologica
|
November 8, 2011
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers
Francesco Zaja, Stefano De Luca, Umberto Vitolo, et al.
British Journal of Haematology
|
December 24, 2021
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial
Annalisa Chiappella, Fary Diop, Claudio Agostinelli, et al.
Journal of Geriatric Oncology
|
July 13, 2019
Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi
Francesco Merli, Federica Cavallo, Flavia Salvi, et al.
Annals of Hematology
|
December 25, 2019
The classic prognostic factors in advanced Hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments
Alessia Bari, Raffaella Marcheselli, Stefano Sacchi, et al.
Haematologica
|
January 18, 2015
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study
Davide Rossi, Alessio Bruscaggin, Piera La Cava, et al.
Leukemia & Lymphoma
|
September 8, 2011
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi
Francesco Merli, Stefano Luminari, Giuseppe Rossi, et al.
Page
of 16